Infliximab biosimilar has shown a safety and efficacy profile in line with the originator both in PsO and PsA patients. The data were obtained from the Biosimiar Registry of the SIDeMAST (Italian National Dermatological Society). Many Italian centres, which had administerd successfully biosimilars in PsO and PsA patients included their own data and the results were presented in this study.
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry / Gisondi P.; Bianchi L.; Conti A.; Dapavo P.; Malagoli P.; Piaserico S.; Savoia F.; Prignano F.; Girolomoni G.. - In: BRITISH JOURNAL OF DERMATOLOGY. - ISSN 0007-0963. - ELETTRONICO. - 177:(2017), pp. e325-e326. [10.1111/bjd.15659]
Infliximab biosimilar CT-P13 in the treatment of chronic plaque psoriasis: data from the Psobiosimilars registry
Savoia F.;Prignano F.;
2017
Abstract
Infliximab biosimilar has shown a safety and efficacy profile in line with the originator both in PsO and PsA patients. The data were obtained from the Biosimiar Registry of the SIDeMAST (Italian National Dermatological Society). Many Italian centres, which had administerd successfully biosimilars in PsO and PsA patients included their own data and the results were presented in this study.
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
